A new white paper from the Network for Excellence in Health Innovation encourages the use of outcomes-based contracting for novel oncology drugs.
Smita Jaggernauth, PharmD
Advertisement
Articles by Smita Jaggernauth, PharmD
A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).
Advertisement
Latest Updated Articles
Mutation May Be Associated With Resistance to NSCLC ImmunotherapyPublished: November 8th 2017 | Updated:
NEHI Recommends Implementing Value-Based Contracts With High-Cost Oncology TreatmentsPublished: November 12th 2017 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Newly Unveiled ACA Premiums Show 26% Average Increase Before Subsidy Expiration
2
Boosting RSV Vaccination in Older Adults Could Save Thousands
3
FDA Guidance to Remove One of the Largest Barriers to Biosimilar Development
4
Real-World Data Key to Optimizing CAR T-Cell Therapy Delivery, Outcomes
5
